Young age at diagnosis has also been associated with a worse clinical outcome, partly because of the over-representation of more aggressive subtypes in young cases compared to older cases, such as triple negative or HER2-positive breast cancer, or because of delayed diagnosis and presentation at an advanced stage [6]. The gene discussed is ERBB2; the disease is breast carcinoma.